Affiliations 

  • 1 Federal University of Sao Paulo State, Sao Paulo, Brazil
  • 2 National University Heart Center, Singapore, Singapore
  • 3 Bioinformatics Institute, ASTAR, Singapore
  • 4 Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Graduate Medical School, Singapore
  • 5 Miller School of Medicine, University of Miami, Miami, Florida
  • 6 Christchurch Heart Institute, University of Otago Christchurch, Christchurch Hospital, Christchurch, New Zealand
  • 7 Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia
  • 8 Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
  • 9 University of Utah, Salt Lake City, Utah
JACC Basic Transl Sci, 2018 Apr;3(2):163-175.
PMID: 30062203 DOI: 10.1016/j.jacbts.2017.12.005

Abstract

We identified a plasma signature of 11 C14 to C26 ceramides and 1 C16 dihydroceramide predictive of major adverse cardiovascular events in patients with acute myocardial infarction (AMI). Among patients undergoing coronary artery bypass surgery, those with recent AMI, compared with those without recent AMI, showed a significant increase in 5 of the signature's 12 ceramides in plasma but not simultaneously-biopsied aortic tissue. In contrast, a rat AMI model, compared with sham control, showed a significant increase in myocardial concentrations of all 12 ceramides and up-regulation of 3 ceramide-producing enzymes, suggesting ischemic myocardium as a possible source of this ceramide signature.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.